BNP Paribas Asset Management
ADMA icon

BNP Paribas Asset Management’s ADMA Biologics ADMA Stock Holding History

BNP Paribas Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8K Sell
3,197
-726
-19% -$6.62K ﹤0.01% 1973
2026
Q1 		$35.3K Buy
3,923
+858
+28% +$13.5K ﹤0.01% 1860
2025
Q4 		$56K Buy
3,065
+836
+38% +$14.1K ﹤0.01% 1627
2025
Q3 		$33K Hold
2,229
– – ﹤0.01% 1188
2025
Q2 		$41K Buy
+2,229
New +$45.5K ﹤0.01% 1209

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BNP Paribas Asset Management's ADMA Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its ADMA Biologics (ADMA) stake by 19% in Q2 2026, selling an estimated $6.62K and leaving 3,197 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1973.

BNP Paribas Asset Management first reported a position in ADMA in Q2 2025 and has held it in 5 quarters since. The position peaked at $56K in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • BNP Paribas Asset Management held 3,197 shares of ADMA Biologics worth $26.8K as of Q2 2026.
  • BNP Paribas Asset Management sold 726 ADMA Biologics shares in Q2 2026, an estimated $6.62K.
  • ADMA Biologics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1973 holding.
  • BNP Paribas Asset Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's ADMA Biologics position peaked at $56K in Q4 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.